EU regulator accepts Sanofi/Regeneron Dupixent product for review
The European Medicines Agency (EMA), the European Union's health regulator, has accepted for review the Dupixent product being developed by drug makers Sanofi and Regeneron, the companies said.
Dupixent is aimed at adults with eczema or moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy.
A biologics license application (BLA) for Dupixent was accepted for Priority Review by the U.S. Food and Drug Administration (FDA) in September 2016.
As per the U.S. Prescription Drug User Fee Act (PDUFA), the target FDA action date is March 29, 2017. The EMA and FDA have conditionally accepted Dupixent as the trade name for dupilumab.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd